OTCMKTS:GTHP Guided Therapeutics (GTHP) Stock Price, News & Analysis $0.10 -0.01 (-6.98%) As of 11/6/2026 01:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Guided Therapeutics Stock (OTCMKTS:GTHP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Guided Therapeutics alerts:Sign Up Key Stats Today's Range$0.10▼$0.1150-Day Range$0.10▼$0.2552-Week Range$0.10▼$0.54Volume56,000 shsAverage Volume60,870 shsMarket Capitalization$9.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Guided Therapeutics, Inc. develops medical devices designed to support the early detection of cancer and precancerous conditions. The company’s primary product is LuViva Advanced Cervical Scan, a noninvasive diagnostic device intended to identify cervical disease by analyzing tissue with light-based technology. LuViva is designed to provide real-time results during an office visit and may help reduce reliance on conventional screening methods that require tissue sampling and laboratory analysis. The company has focused on applications in women’s health, particularly cervical cancer screening and the detection of cervical precancer. Guided Therapeutics is based in the United States and has pursued regulatory clearances, commercialization, and international distribution opportunities for its diagnostic technology. Publicly available company information is limited, and details regarding its current leadership and geographic operations may change over time.AI Generated. May Contain Errors. Read More Guided Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreGTHP MarketRank™: 0.60762942779 of 5 starsGuided Therapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Guided Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Guided Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guided Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Guided Therapeutics has been sold short.Short Interest Ratio / Days to CoverGuided Therapeutics has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Guided Therapeutics has recently decreased by 53.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGuided Therapeutics does not currently pay a dividend.Dividend GrowthGuided Therapeutics does not have a long track record of dividend growth. News and Social Media0.4 / 5News SentimentN/A News SentimentGuided Therapeutics has a news sentiment score of -1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Guided Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for GTHP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Guided Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders66.83% of the stock of Guided Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions9.69% of the stock of Guided Therapeutics is held by institutions.Read more about Guided Therapeutics' insider trading history. Receive GTHP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guided Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GTHP Stock News HeadlinesGuided Therapeutics Provides Update on its Cervical Cancer Screening Study with Türkiye’s Ministry of HealthNovember 4, 2026 | finance.yahoo.comGuided Therapeutics Reaches Collaborative Agreement with Türkiye’s Ministry of Health to Become Primary Screening Test for Cervical CancerSeptember 9, 2026 | finance.yahoo.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 8 at 1:00 AM | Behind the Markets (Ad)Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese DistributorJuly 22, 2026 | finance.yahoo.comGuided Therapeutics Announces New Agreement with Distribution Partner Yuanshuo Medical Instruments CorporationJuly 14, 2026 | uk.finance.yahoo.comGuided Therapeutics Files Premarket Approval Application Clinical Report with FDAJune 16, 2026 | businesswire.comGuided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant OfferingMarch 31, 2026 | finance.yahoo.comAnalysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuVivaDecember 17, 2025 | finance.yahoo.comSee More Headlines GTHP Stock Analysis - Frequently Asked Questions How have GTHP shares performed this year? Guided Therapeutics' stock was trading at $0.54 on January 1st, 2026. Since then, GTHP stock has decreased by 81.5% and is now trading at $0.10. How were Guided Therapeutics' earnings last quarter? Guided Therapeutics Inc. (OTCMKTS:GTHP) posted its earnings results on Thursday, August, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of Guided Therapeutics? Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today11/08/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolOTCMKTS:GTHP CIK924515 Webwww.guidedinc.com Phone(770) 242-8723Fax770-242-8639Employees3Year Founded1992Profitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.20 million Net MarginsN/A Pretax Margin-471.23% Return on EquityN/A Return on Assets-243.93% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick RatioN/A Sales & Book Value Annual Sales$770 thousand Price / Sales12.75 Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-1.11Miscellaneous Outstanding Shares98,190,000Free Float32,569,000Market Cap$9.82 million OptionableNot Optionable Beta0.78 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:GTHP) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredA monthly income idea that does not require selling sharesA $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guided Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guided Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
